Advertisement

Reactions Weekly

, Volume 1739, Issue 1, pp 103–103 | Cite as

Cytarabine/etoposide/mitoxantrone

Secondary chemo-resistance: 4 case reports
Case report
  • 8 Downloads
Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

  • * death

  • * life-threatening

  • * hospitalisation

  • * disability

  • * congenital anomaly

  • * other medically important event

In a study of 44 paediatric patients, two boys and two girls aged 10−14 years old were described, who developed secondary chemo-resistance to mitoxantrone, cytarabine and etoposide during treatment for acute myeloid leukaemia (AML) [dosages and routes not stated].

Patient 1: The 10-year-old girl was diagnosed with AML. She showed lack of mutations in the dominant clone. Induction chemotherapy with mitoxantrone, cytarabine and etoposide was administered and a complete response was noted. Six months later, a relapse was noted. Therefore, she received induction chemotherapy with mitoxantrone, cytarabine and etoposide, following which a partial response was noted. The bone marrow (BM) blasts % by morphology, which was 83.50 at baseline and 0.45 after the first induction chemotherapy...

Reference

  1. Zhan D, et al. Whole exome sequencing identifies novel mutations of epigenetic regulators in chemorefractory pediatric acute myeloid leukemia. Leukemia Research 65: 20-24, Feb 2018. Available from: URL: http://doi.org/10.1016/j.leukres.2017.12.001 - ChinaCrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Personalised recommendations